Pharmacokinetics — Metabolism

Drug metabolism refers to the biochemical modification of a drug molecule within the body, most commonly through enzymatic processes, to convert lipophilic (fat-soluble) compounds into more hydrophilic (water-soluble) metabolites that can be eliminated from the body. While the liver is the primary site of drug metabolism, extrahepatic tissues — including the gastrointestinal tract, lungs, kidneys, and skin — also contribute significantly to the metabolic fate of many drugs. Understanding drug metabolism is essential for predicting drug efficacy, duration of action, potential toxicity, and the likelihood of drug-drug interactions. For the SAPC (South African Pharmacy Council) examination, candidates must demonstrate a thorough grasp of metabolic pathways, the enzymes involved, the factors that alter metabolic capacity, and the clinical consequences of these alterations.

The overall purpose of drug metabolism can be summarised as the body’s attempt to convert pharmacologically active, often lipophilic substances into inactive, water-soluble compounds that can be readily excreted via the kidneys or bile. However, metabolism is not always a detoxification process. In some cases, metabolism produces metabolites that are more pharmacologically active than the parent compound (active metabolites), or metabolites that are actually more toxic (toxic activation). This concept is critical in pharmacology and forms the basis of prodrug design — drugs that are administered in an inactive form and require metabolic activation to exert their therapeutic effect.

---

1. Sites of Drug Metabolism

1.1 Hepatic Metabolism

The liver is the principal organ responsible for drug metabolism, owing to its rich blood supply, large mass, and high concentration of metabolic enzymes. Blood flowing from the gastrointestinal tract passes through the liver via the portal vein before reaching the systemic circulation, a pathway known as the first-pass effect. This anatomical arrangement means that drugs absorbed from the gastrointestinal tract are exposed to hepatic metabolism before they can distribute to their target tissues. The implications of first-pass metabolism are profound: many drugs exhibit significantly reduced oral bioavailability because of extensive hepatic extraction, and the dose required for oral administration may be substantially higher than the dose required for intravenous administration to achieve the same systemic exposure.

Hepatocytes (liver cells) contain two major categories of metabolic enzymes, classified by the type of biochemical reaction they catalyse. Phase I reactions (functionalisation reactions) introduce or expose a functional group on the drug molecule through oxidation, reduction, or hydrolysis. Phase II reactions (conjugation reactions) attach an endogenous substrate — such as glucuronic acid, sulfate, or an amino acid — to the drug molecule or its Phase I metabolite, producing a highly water-soluble conjugate that is readily excreted. It is important to note that not all drugs undergo both phases; some drugs are eliminated by Phase I reactions alone, others by Phase II alone, and some bypass metabolism entirely to be excreted unchanged.

1.2 Extrahepatic Metabolism

While the liver dominates drug metabolism, several extrahepatic tissues play clinically significant roles. The gastrointestinal tract is particularly important for drugs administered orally. The intestinal mucosa expresses cytochrome P450 enzymes — most notably CYP3A4 — as well as drug efflux transporters such as P-glycoprotein. These proteins act in concert to limit the absorption of many drugs, contributing substantially to the first-pass effect and oral bioavailability. The gut flora also contributes to drug metabolism through bacterial enzymes that can perform reductions, hydrolyses, and decarboxinations that complement human metabolic pathways.

The kidneys contain metabolic enzymes involved in the activation of vitamin D and the metabolism of certain drugs, while the lungs express CYP enzymes capable of metabolising inhaled anaesthetics and other volatile agents. The skin contains esterases involved in the hydrolysis of topical prodrugs, and the brain — particularly the microglia — expresses lower levels of CYP enzymes that may contribute to the metabolism of centrally acting drugs. The clinical significance of extrahepatic metabolism varies depending on the drug and the route of administration, but in total these tissues represent a meaningful component of overall drug clearance.

---

2. Phase I Reactions: Functionalisation

Phase I reactions are primarily oxidative, though reductions and hydrolyses also occur. These reactions generally convert the parent drug into a more polar metabolite by introducing or unmasking a functional group (-OH, -NH₂, -SH, -COOH) that can serve as a site for Phase II conjugation. The most important Phase I enzyme system is the cytochrome P450 mixed-function oxidase system, which accounts for the metabolism of the majority of clinically used drugs.

2.1 The Cytochrome P450 System

The cytochrome P450 (CYP) system is a superfamily of haem-containing enzymes located primarily in the smooth endoplasmic reticulum of hepatocytes. The name “cytochrome P450” derives from the characteristic absorption maximum at 450 nm of the carbon monoxide-bound form of the reduced enzyme. These enzymes catalyse the monooxygenation of their substrate: one atom of molecular oxygen is incorporated into the substrate (forming a hydroxylated product), while the other is reduced to water, requiring NADPH as a cofactor.

The CYP system is classified into families and subfamilies based on amino acid sequence homology. Enzymes sharing more than 40% sequence identity are grouped into the same family (designated by an Arabic numeral, e.g., CYP3), while those sharing more than 55% identity are grouped into the same subfamily (designated by a letter, e.g., CYP3A). The most clinically important isoforms in human drug metabolism belong to the CYP1, CYP2, and CYP3 families. Within these, six enzymes are responsible for the metabolism of approximately 90% of clinically used drugs: CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5.

2.1.1 CYP1A2

CYP1A2 accounts for approximately 13% of hepatic CYP expression and is involved in the metabolism of several clinically important drugs. It is notable for its involvement in the metabolism of theophylline, caffeine, clozapine, olanzapine, and several antidepressants. CYP1A2 is inducible by cigarette smoking and char-grilled meat (polycyclic aromatic hydrocarbons) and is inhibited by fluvoxamine, ciprofloxacin, and certain flavonoids. Induction of CYP1A2 increases the metabolic clearance of its substrates; for example, a smoker may require higher doses of theophylline to achieve therapeutic concentrations, and when smoking cessation occurs, the dose must be reduced to avoid toxicity. This is a classic and commonly examined drug-drug interaction scenario.

Key substrates of CYP1A2:

• Theophylline (narrow therapeutic index — clinical significance of induction/inhibition is high)
• Caffeine (interactions with ciprofloxacin and fluvoxamine are well-documented)
• Clozapine and olanzapine (antipsychotic dose adjustments may be needed with inducers or inhibitors)
• Tacrine (acetylcholinesterase inhibitor, now largely obsolete)

South African clinical context: Smoking remains prevalent in South Africa, particularly among communities with limited access to healthcare education. South African pharmacists should be aware that smoking-induced CYP1A2 induction is clinically relevant when dispensing theophylline-containing products, which are still used in some public sector facilities for asthma management. Patients should be counselled that smoking increases theophylline clearance and that quitting smoking — a goal that pharmacists actively support — will reduce clearance and may necessitate dose reduction.

2.1.2 CYP2C9

CYP2C9 is a clinically critical enzyme given its role in the metabolism of warfarin, phenytoin, losartan, and numerous non-steroidal anti-inflammatory drugs. CYP2C9 demonstrates genetic polymorphism (see Section 6), and patients with reduced CYP2C9 activity are at significantly increased risk of warfarin-related bleeding events because of impaired clearance of the more potent S-enantiomer of warfarin. Dose individualisation based on genotype is increasingly incorporated into warfarin prescribing algorithms in South Africa, particularly in specialised anticoagulation clinics.

Key substrates of CYP2C9:

• Warfarin (S-warfarin is metabolised primarily by CYP2C9; impaired metabolism leads to supratherapeutic INR)
• Phenytoin (narrow therapeutic index; CYP2C9 polymorphism contributes to phenytoin toxicity)
• Losartan (CYP2C9 converts losartan to its active metabolite E-3174)
• Ibuprofen and other NSAIDs (CYP2C9-mediated metabolism is a contributor, not the sole pathway)
• Fluvastatin

Inhibitors of CYP2C9 include amiodarone, fluconazole, metronidazole, and sulfamethoxazole. Concomitant use of these inhibitors with warfarin requires close monitoring of INR. Inducers include rifampicin, carbamazepine, and phenobarbital, which reduce warfarin efficacy and necessitate INR monitoring and dose adjustment.

2.1.3 CYP2C19

CYP2C19 is responsible for the metabolism of proton pump inhibitors (omeprazole, esomeprazole, lansoprazole), clopidogrel (activation step — see prodrug section), certain antidepressants (sertraline, amitriptyline), and diazepam. Like CYP2C9, CYP2C19 exhibits genetic polymorphism, with poor metabolisers constituting approximately 2–5% of the South African population, though allele frequencies vary across population groups. The distribution of CYP2C19 variant alleles (particularly CYP2C192 and CYP2C1917) differs between African, Asian, and European populations, and South Africa’s diverse genetic heritage means that allelic frequencies must be considered in clinical practice.

CYP2C19 and clopidogrel is one of the most clinically significant drug-metabolism interactions in modern medicine. Clopidogrel is a prodrug that requires bioactivation by CYP2C19 (among other enzymes). Patients who are CYP2C19 poor metabolisers achieve substantially lower levels of the active metabolite and are at increased risk of cardiovascular events when treated with clopidogrel following acute coronary syndrome or percutaneous coronary intervention. This interaction has led toboxed warnings on clopidogrel labelling and has prompted interest in alternative antiplatelet strategies such as ticagrelor or prasugrel, which do not require CYP2C19-mediated activation.

South African context: The South African Heart and Stroke Foundation and the South African Medical Research Council have highlighted the clopidogrel-CYP2C19 interaction as clinically important in the South African context, where resource constraints mean that ticagrelor may not be readily available in all public healthcare settings. Pharmacists dispensing clopidogrel should be aware of the interaction and consider the need for therapeutic monitoring or referral for genotype testing where available.

2.1.4 CYP2D6

CYP2D6 is one of the most extensively studied polymorphic CYP enzymes and is responsible for the metabolism of approximately 25% of commonly used drugs, including opioids (codeine, tramadol, morphine via conversion), beta-blockers (metoprolol, carvedilol), antidepressants (fluoxetine, paroxetine, nortriptyline), antipsychotics (haloperidol, risperidone), and antiemetics (ondansetron, though it is also metabolised by other pathways). Unlike CYP1A2, CYP2C9, CYP2C19, and CYP3A4, CYP2D6 is not inducible — its activity is determined entirely by genetic constitution. However, it is susceptible to potent inhibition by many drugs.

The codeine-tramadol-morphine pathway is of particular clinical significance. Codeine is O-demethylated by CYP2D6 to produce morphine, which is responsible for codeine’s analgesic effect. In CYP2D6 ultra-rapid metabolisers, excessive morphine production can lead to dangerous opioid toxicity, including respiratory depression. In poor metabolisers, codeine produces minimal analgesia because of insufficient conversion to morphine. This has led to regulatory contraindications on codeine-containing products in several countries. In South Africa, the South African Health Products Regulatory Authority (SAHPRA) has similarly restricted codeine-containing products, requiring prescriptions and implementing scheduling changes to limit over-the-counter access due to the risk of opioid toxicity in ultra-rapid metabolisers and the risk of inadequate analgesia in poor metabolisers.

Tramadol is metabolised by CYP2D6 to O-desmethyltramadol (M1), which is more potent than the parent compound. Ultra-rapid metabolisers are at increased risk of seizures and serotonin syndrome with tramadol, while poor metabolisers experience reduced analgesia.

2.1.5 CYP3A4 and CYP3A5

CYP3A4 is the most abundant CYP enzyme in the human liver (approximately 30% of total hepatic CYP content) and is responsible for the metabolism of more drugs than any other single enzyme. CYP3A5 is a closely related enzyme with overlapping substrate specificity, but its expression is highly variable and is largely determined by genetic polymorphisms. CYP3A4 is predominantly located in the liver and intestinal mucosa, making it uniquely positioned to contribute to both first-pass metabolism (intestinal CYP3A4) and systemic clearance (hepatic CYP3A4).

Major substrates of CYP3A4 include:

• Calcium channel blockers (verapamil, diltiazem, nifedipine)
• Statins (simvastatin, atorvastatin, lovastatin — though pravastatin and rosuvastatin have less CYP3A4 involvement)
• Immunosuppressants (cyclosporine, tacrolimus, sirolimus)
• Benzodiazepines (alprazolam, midazolam, triazolam)
• Macrolide antibiotics (erythromycin, clarithromycin — also potent CYP3A4 inhibitors)
• Antiretrovirals (protease inhibitors, non-nucleoside reverse transcriptase inhibitors)
• Oral contraceptives (steroid hormones)
• Carbamazepine (CYP3A4 substrate and potent inducer)

CYP3A4 induction and inhibition represent some of the most clinically significant drug-drug interactions. Inducers (such as rifampicin, carbamazepine, phenytoin, phenobarbital, St. John’s Wort) dramatically increase CYP3A4 activity, reducing plasma concentrations of substrate drugs and potentially causing therapeutic failure. Inhibitors (such as ketoconazole, itraconazole, erythromycin, clarithromycin, protease inhibitors, grapefruit juice) decrease CYP3A4 activity, increasing plasma concentrations of substrate drugs and potentially causing toxicity.

The interaction between grapefruit juice and statins is a frequently tested topic in pharmacy examinations. Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal CYP3A4 (not hepatic CYP3A4), increasing the oral bioavailability of CYP3A4 substrate drugs. The effect is most pronounced with simvastatin and lovastatin, and patients should be counselled to avoid grapefruit juice when taking these medications, or to switch to a statin with minimal CYP3A4 metabolism such as pravastatin or rosuvastatin.

Table 1: Major Cytochrome P450 Enzymes — Summary

Enzyme	% of Hepatic CYP	Key Substrates	Prototypical Inhibitors	Prototypical Inducers	Clinical Significance
CYP1A2	~13%	Theophylline, caffeine, clozapine, olanzapine	Fluvoxamine, ciprofloxacin, fluoroquinolones	Tobacco smoke, char-grilled meat, omeprazole	Smoking cessation changes theophylline requirements
CYP2C9	~15%	Warfarin, phenytoin, losartan, NSAIDs	Amiodarone, fluconazole, metronidazole, TMP-SMX	Rifampicin, carbamazepine, phenobarbital	Warfarin dose individualisation; bleeding risk
CYP2C19	~20%	PPIs, clopidogrel (activation), diazepam, sertraline	Omeprazole, esomeprazole, fluoxetine, cimetidine	Rifampicin, carbamazepine	Clopidogrel efficacy in poor metabolisers
CYP2D6	~2% (but metabolises ~25% of drugs)	Codeine, tramadol, metoprolol, fluoxetine, haloperidol	Quinidine, paroxetine, fluoxetine, bupropion	Not inducible	Opioid toxicity in ultra-rapid metabolisers; analgesic failure in poor metabolisers
CYP3A4	~30%	Calcium channel blockers, statins, immunosuppressants, midazolam	Ketoconazole, erythromycin, clarithromycin, grapefruit juice, ritonavir	Rifampicin, carbamazepine, phenytoin, St. John’s Wort	Largest number of drug-drug interactions of any single enzyme

---

2.2 Other Phase I Enzymes

While the CYP system dominates Phase I metabolism, several non-CYP enzymes are also clinically important.

Flavin-containing monooxygenases (FMOs) catalyse the oxidation of nucleophilic heteroatoms (particularly nitrogen and sulfur) to their corresponding oxides and is several drugs including nicotine, tamoxifen, and itopride. FMOs are not induced or inhibited by the same agents as CYP enzymes, making them an important alternative metabolic pathway in some contexts.

Alcohol dehydrogenases and aldehyde dehydrogenases metabolise ethanol and can be involved in the metabolism of certain drugs that contain hydroxyl groups. The well-known disulfiram-like reaction — in which drugs such as metronidazole, certain cephalosporins, and chlorpropamide inhibit aldehyde dehydrogenase, causing accumulation of acetaldehyde when alcohol is consumed — is a clinically important interaction that pharmacists should counsel patients about.

Esterases catalyse the hydrolysis of ester bonds and are responsible for the metabolism of several important drug classes, including aspirin (hydrolysed by plasma and tissue esterases to salicylate and acetate), local anaesthetics (procaine, cocaine), angiotensin-converting enzyme (ACE) inhibitors (quinapril, ramipril — prodrugs that undergo ester hydrolysis to their active forms), and succinylcholine (metabolised by plasma cholinesterase). Genetic variants of plasma cholinesterase (pseudocholinesterase deficiency) lead to prolonged neuromuscular blockade following succinylcholine administration, a classic exam topic related to pharmacogenetics.

Monoamine oxidases (MAOs) metabolise monoamine neurotransmitters and are the target of MAO inhibitor antidepressants. MAO-A metabolises serotonin, norepinephrine, and dopamine; MAO-B metabolises dopamine and phenylethylamine. The interaction between MAO inhibitors and tyramine-containing foods (aged cheeses, cured meats, fermented foods, red wine) is a well-known hypertensive crisis risk — the “cheese reaction” — which is particularly important in South Africa where traditional foods such as dried beef (biltong) and fermented milk products may contain significant tyramine. Patients taking MAO inhibitors should receive detailed dietary counselling from their pharmacist.

---

2.3 Phase I Reaction Types

2.3.1 Oxidation

Oxidation is the most common Phase I reaction and the primary function of the CYP system. The range of oxidative reactions catalysed by CYP enzymes is extensive and includes:

Aliphatic hydroxylation: The introduction of a hydroxyl group into a straight-chain or branched aliphatic side chain, converting a relatively lipophilic alkyl group into a more polar alcohol. Example: phenytoin undergoes aromatic oxidation and aliphatic side-chain hydroxylation.

Aromatic hydroxylation: The introduction of a hydroxyl group onto an aromatic ring, producing a phenol. Example: phenytoin, propranolol, and many other drugs with aromatic rings undergo this reaction.

Epoxidation: The formation of an epoxide (three-membered cyclic ether) from a double bond. Epoxides are generally more reactive and potentially more toxic than the parent compound. Carbamazepine is metabolised to carbamazepine-10,11-epoxide, which is pharmacologically active and contributes to both efficacy and toxicity.

N-dealkylation: The removal of an alkyl group from a nitrogen atom, producing a secondary or primary amine and an aldehyde. Examples include the N-demethylation of amitriptyline to nortriptyline, and the N-demethylation of caffeine to theobromine and theophylline.

O-dealkylation: The removal of an alkyl group from an oxygen atom, producing a phenol and an aldehyde. Codeine undergoes O-demethylation to morphine (mediated by CYP2D6), and methoxy groups on various drugs are susceptible to O-dealkylation.

S-oxidation: The oxidation of sulfur-containing compounds to sulfoxides or sulfones. Cimetidine undergoes S-oxidation, and the thiazide diuretics are metabolised in part by S-oxidation.

Deamination: The oxidative removal of an amino group, converting primary amines to alcohols with release of ammonia.

2.3.2 Reduction

Reductive reactions are less common than oxidative reactions and occur primarily in anaerobic conditions, such as in the gastrointestinal lumen or in hypoxic liver tissue. Azo and nitro groups can be reduced to amines by bacterial and hepatic enzymes. Chloramphenicol undergoes nitro group reduction, and the azo prodrug sulfasalazine is reduced by colonic bacteria to release 5-aminosalicylic acid (the active moiety) and sulfapyridine.

2.3.3 Hydrolysis

Hydrolytic reactions cleave ester and amide bonds by adding water. Esterases (including acetylcholinesterase, plasma cholinesterase, and tissue esterases) catalyse the hydrolysis of ester-containing drugs such as aspirin, succinylcholine, and esmolol. Amidase enzymes hydrolyse amide bonds, though amides are generally more resistant to hydrolysis than esters, contributing to their longer duration of action. Procainamide is hydrolysed to p-aminobenzoic acid (PABA) derivatives, and the hydrolysis of amide local anaesthetics contributes to their termination of action.

---

3. Phase II Reactions: Conjugation

Phase II reactions involve the attachment of an endogenous conjugating molecule to the drug (or its Phase I metabolite) to produce a highly water-soluble, inactive conjugate that can be readily excreted. Phase II reactions are generally considered detoxification pathways, though some conjugates can be chemically reactive and potentially toxic. The conjugating enzymes are located primarily in the cytosol of hepatocytes, unlike most Phase I enzymes which are bound to the smooth endoplasmic reticulum.

The general pathway involves activation of the endogenous substrate to a high-energy intermediate (often using ATP), followed by transfer of the activated conjugate to the drug molecule by a specific transferase enzyme. The result is a metabolite with substantially increased molecular weight and polarity, facilitating renal or biliary excretion.

3.1 Glucuronidation

Glucuronidation is the most common Phase II reaction and involves the transfer of glucuronic acid from the high-energy donor uridine diphosphate-glucuronic acid (UDPGA) to a drug or Phase I metabolite containing a hydroxyl, carboxyl, amine, or sulfhydryl group. The reaction is catalysed by the family of UDP-glucuronosyltransferase (UGT) enzymes. Glucuronides are substantially more water-soluble than their parent compounds and are readily excreted in urine or bile. Some glucuronides — particularly those formed from arylamine carcinogens — can be hydrolysed by beta-glucuronidase in the gastrointestinal tract, potentially leading to reabsorption of the parent compound or carcinogen (enterohepatic recirculation).

Important drugs metabolised by glucuronidation:

• Lorazepam, oxazepam, temazepam (benzodiazepines — these “intermediate” benzodiazepines undergo glucuronidation rather than CYP oxidation, making them preferable in patients with liver disease)
• Morphine (morphine-6-glucuronide is pharmacologically active and contributes to analgesic effect)
• Paracetamol (paracetamol-glucuronide is a major metabolite; a small fraction is shunted to the toxic intermediate N-acetyl-p-benzoquinone imine, NAPQI)
• Lamotrigine (glucuronidation is the primary metabolic pathway)
• Mycophenolic acid (the active form of mycophenolate mofetil, an immunosuppressant)
• Ethinylestradiol (partial glucuronidation)
• Zidovudine (azidothymidine, AZT — glucuronidation is the primary clearance mechanism)

Genetic polymorphisms in UGT enzymes are clinically relevant. UGT1A1 deficiency causes Gilbert’s syndrome (mild unconjugated hyperbilirubinaemia) and also impairs the metabolism of drugs such as irinotecan, whose active metabolite SN-38 is detoxified by UGT1A1. UGT2B7 is involved in morphine glucuronidation and is polymorphic, potentially contributing to interindividual variability in morphine response.

South African context: The prevalence of Gilbert’s syndrome in South Africa is similar to global estimates (approximately 5–10% of the population). Patients with undiagnosed Gilbert’s syndrome may have altered drug metabolism, though the clinical significance is generally limited. More importantly, the use of UGT inhibitors (such as valproic acid, which inhibits glucuronidation pathways) in combination with drugs primarily cleared by glucuronidation warrants caution.

3.2 Sulfation

Sulfation involves the transfer of a sulfate group from the donor 3’-phosphoadenosine-5’-phosphosulfate (PAPS) to a hydroxyl or amine group on the drug molecule, catalysed by sulfotransferase enzymes. Sulfation generally produces inactive metabolites, though in some cases (such as the metabolism of minoxidil or acetaminophen), sulfate metabolites contribute to or are responsible for pharmacological activity. Sulfation is a high-capacity but low-affinity pathway — at low substrate concentrations, sulfation predominates, but at higher concentrations (as occurs in paracetamol overdose), the sulfation pathway becomes saturated and a greater proportion of drug is shunted to CYP-mediated oxidation, producing the toxic NAPQI metabolite.

Important drugs metabolised by sulfation:

• Paracetamol (acetaminophen — sulfation is a minor but significant pathway at therapeutic doses)
• Methyldopa
• Salbutamol (albuterol — sulfation is a major metabolic pathway for inhaled beta-agonists)
• Estradiol and ethinylestradiol
• Triclosan (antimicrobial)
• Minoxidil (sulfate metabolite is the active species responsible for vasodilation)

3.3 Acetylation

Acetylation involves the transfer of an acetyl group from acetyl-CoA to a primary amine, hydroxyl, or hydrazine group on the drug molecule, catalysed by N-acetyltransferase (NAT) enzymes. Acetylation occurs in the liver and gastrointestinal mucosa and is notable for its genetic polymorphism: individuals are classified as slow acetylators or fast (rapid) acetylators based on their NAT2 genotype. The frequency of slow acetylator phenotype varies substantially between populations — it is approximately 50–60% in Caucasian and African populations and 10–30% in Asian populations. In South Africa, both phenotypes are represented across population groups, with some variation in allelic frequencies.

Important drugs metabolised by acetylation:

• Isoniazid (slow acetylators are at increased risk of peripheral neuropathy due to accumulation of isoniazid; also increased risk of lupus-like syndrome)
• Hydralazine (slow acetylators are at increased risk of drug-induced lupus)
• Procainamide (slow acetylators have higher risk of agranulocytosis and drug-induced lupus)
• Sulfonamides (acetylation is a major metabolic pathway; slow acetylators may be at increased risk of crystalluria with sulfamethoxazole)
• Dapsone (acetylation contributes to clearance; used in leprosy treatment, which remains relevant in South Africa)

Clinical implications of slow acetylation: In addition to the adverse effects listed above, slow acetylators may experience prolonged drug effects and increased toxicity when treated with drugs primarily cleared by acetylation. This is particularly relevant for isoniazid in the treatment of tuberculosis, which remains a major public health challenge in South Africa. The South African National Tuberculosis Programme incorporates isoniazid preventive therapy, and pharmacists dispensing isoniazid should be aware that slow acetylators require dose adjustment or more frequent monitoring for neurotoxicity.

3.4 Methylation

Methylation involves the transfer of a methyl group from S-adenosylmethionine (SAM) to a hydroxyl, amine, or sulfur group on the drug molecule, catalysed by methyltransferase enzymes. Methylation generally reduces the pharmacological activity of the drug, though some methylated metabolites retain activity comparable to or greater than the parent compound. Methylation is a less common Phase II pathway than glucuronidation or sulfation.

Important drugs metabolised by methylation:

• Captopril (S-methylation is a metabolic pathway)
• 6-Mercaptopurine and azathioprine (methylation by thiopurine methyltransferase, TPMT — TPMT polymorphism is clinically critical; see Section 6)
• Methyldopa (alpha-methyldopa is both a metabolite and a false neurotransmitter)
• Epinephrine and norepinephrine (metabolism by catechol-O-methyltransferase, COMT — COMT inhibitors used in Parkinson’s disease prolong dopamine availability)

TPMT and azathioprine/6-mercaptopurine is a critically important metabolic pathway in clinical practice. TPMT deficiency (affecting approximately 1 in 300 individuals as poor metabolisers) leads to severe, life-threatening myelosuppression when standard doses of azathioprine or 6-mercaptopurine are administered, because the thiopurine drugs accumulate and are converted to toxic metabolites that would otherwise be inactivated by TPMT methylation. In South Africa, TPMT testing is recommended before initiating thiopurine therapy and is available through several tertiary hospitals and laboratory services. Pharmacists dispensing these medications should confirm that TPMT testing has been performed.

3.5 Glutathione Conjugation

Glutathione (GSH) conjugation involves the nucleophilic attack of the thiol group of glutathione on electrophilic drug metabolites, producing a mercapturic acid conjugate that is highly water-soluble and can be excreted in bile or urine. Glutathione conjugation is a critical detoxification pathway for reactive electrophilic metabolites, including the toxic metabolites produced during the metabolism of paracetamol (NAPQI), halogenated hydrocarbons, and certain chemotherapeutic agents.

Paracetamol (acetaminophen) hepatotoxicity is the classic example of the importance of glutathione conjugation. At therapeutic doses, a small fraction of paracetamol is oxidised by CYP enzymes (primarily CYP2E1 and CYP3A4) to NAPQI, a highly electrophilic and hepatotoxic metabolite. NAPQI is rapidly detoxified by conjugation with glutathione. At toxic doses (typically >150 mg/kg in adults, or chronic supratherapeutic ingestion), glutathione stores become depleted, NAPQI accumulates, and it binds covalently to hepatic proteins, causing hepatocellular necrosis. The antidote is N-acetylcysteine (NAC), which replenishes glutathione stores and can also directly conjugate NAPQI. This mechanism is a high-priority topic for the SAPC examination, and candidates should understand the time-dependence of paracetamol toxicity: the risk of hepatotoxicity is greatest when NAC is administered more than 8–10 hours after ingestion.

Other drugs metabolised by glutathione conjugation include the anticancer agents busulfan and cyclophosphamide (which produces the toxic metabolite acrolein, detoxified by glutathione), and several antibiotics and anticonvulsants that produce reactive intermediates.

3.6 Amino Acid Conjugation

Amino acid conjugation involves the attachment of an amino acid (most commonly glycine, glutamine, or taurine) to a drug molecule containing a carboxylic acid group. The reaction requires prior activation of the drug to a coenzyme A (CoA) ester. This pathway is responsible for the metabolism of benzoic acid (and by extension, salicylates), certain NSAIDs, and some aromatic acids.

Table 2: Phase II Conjugation Reactions — Summary

Conjugation Type	Endogenous Donor	Enzyme	Site	Key Drug Substrates	Clinical Notes
Glucuronidation	UDPGA	UDP-glucuronosyltransferase (UGT)	ER (microsomes)	Lorazepam, morphine, paracetamol, lamotrigine	Most common Phase II reaction; Gilbert’s syndrome affects UGT1A1
Sulfation	PAPS	Sulfotransferase (SULT)	Cytosol	Paracetamol, salbutamol, estrone, minoxidil	High-capacity, low-affinity; saturates at high substrate concentrations
Acetylation	Acetyl-CoA	N-acetyltransferase (NAT1, NAT2)	Cytosol	Isoniazid, hydralazine, procainamide, sulfonamides	Genetic polymorphism: slow vs rapid acetylators; important in TB treatment
Methylation	SAM	Methyltransferase	Cytosol	6-MP/azathioprine (TPMT), methyldopa, captopril	TPMT deficiency causes severe myelosuppression with thiopurines
Glutathione conjugation	Glutathione (GSH)	Glutathione-S-transferase (GST)	Cytosol	Paracetamol (NAPQI), cyclophosphamide, busulfan	Depletion causes accumulation of toxic metabolites
Amino acid conjugation	Glycine, glutamine, taurine	Acyl-CoA synthetase + N-acyltransferase	Mitochondria	Benzoic acid, salicylates, certain NSAIDs	Clinically less prominent than other pathways

---

4. First-Pass Metabolism

First-pass metabolism refers to the phenomenon whereby a drug administered orally is partially metabolised before reaching the systemic circulation, as it passes through the gastrointestinal lumen, the intestinal mucosa, the portal circulation, and the liver before entering the hepatic veins and systemic circulation. The fraction of the administered dose that reaches the systemic circulation unchanged is termed the bioavailability (F). Drugs with extensive first-pass metabolism have low oral bioavailability and require proportionally higher oral doses than intravenous doses to achieve equivalent systemic exposure.

The extent of first-pass metabolism is described by the extraction ratio (E), which is the fraction of drug extracted (metabolised) by the liver during a single pass. Drugs are classified as high-extraction drugs (E > 0.7) or low-extraction drugs (E < 0.3). In high-extraction drugs, hepatic clearance is flow-limited — that is, it depends primarily on hepatic blood flow rather than the intrinsic metabolic capacity of the liver. In low-extraction drugs, clearance depends more on the intrinsic activity of metabolising enzymes than on blood flow.

Examples of drugs with extensive first-pass metabolism:

• Propranolol (approximately 90% first-pass extraction; oral dose is approximately 20–40% of IV dose to achieve equivalent systemic exposure)
• Lidocaine (not given orally due to extensive first-pass metabolism)
• Nitroglycerin (extensive first-pass metabolism is why sublingual and transdermal routes are preferred)
• Morphine (oral bioavailability is approximately 30–40% due to first-pass metabolism)
• Verapamil (extensive first-pass; oral bioavailability is 20–30% of IV)
• Testosterone (undergoes extensive first-pass hepatic metabolism; transdermal patches avoid this)

Clinical implications of first-pass metabolism: When first-pass metabolism is bypassed — by using sublingual, transdermal, intramuscular, or intravenous routes — much lower doses can achieve equivalent or greater systemic exposure. This is exploited clinically with nitroglycerin (given sublingually or transdermally to avoid first-pass metabolism and achieve rapid coronary vasodilation) and with testosterone (given as transdermal patches or gels to bypass hepatic metabolism and achieve adequate serum testosterone levels).

South African clinical context: The availability of different formulations in the South African public sector is sometimes limited by cost considerations. For example, nitroglycerin sublingual tablets may be more readily available than transdermal patches in primary healthcare facilities, and pharmacists should ensure that patients understand the correct sublingual administration technique to ensure adequate drug absorption. Additionally, oral morphine formulations used for chronic pain in South Africa require upward titration because of the limited oral bioavailability, and the South African Palliative Care Guidelines recommend higher oral doses relative to parenteral doses.

---

5. Prodrugs and Metabolic Activation

A prodrug is a pharmacologically inactive compound that is converted by metabolic processes in the body to an active drug. Prodrug design is a deliberate strategy used to improve drug absorption, increase bioavailability, reduce toxicity, or target drug delivery to specific tissues. Understanding prodrug activation pathways is critical because genetic polymorphisms or drug interactions that affect the activating metabolic enzymes directly impact the efficacy and safety of prodrug therapy.

5.1 Clinically Important Prodrugs

Clopidogrel is a thienopyridine antiplatelet agent that requires hepatic CYP-mediated bioactivation. Approximately 85% of an administered dose of clopidogrel is hydrolysed by esterases to an inactive carboxylic acid metabolite (SR-26334). The remaining 15% undergoes sequential CYP-mediated oxidation — primarily by CYP2C19 and CYP1A2 and to a lesser extent by CYP2B6, CYP2C9, and CYP3A4 — to produce the active thiol metabolite (H3), which irreversibly inhibits the P2Y12 ADP receptor on platelets. As discussed in Section 2.1.3, CYP2C19 poor metabolisers generate insufficient active metabolite and are at increased risk of cardiovascular events.

Codeine is a prodrug whose analgesic effect is entirely dependent on CYP2D6-mediated conversion to morphine. The polymorphic nature of CYP2D6 means that codeine’s efficacy is highly variable: poor metabolisers may experience no analgesia, while ultra-rapid metabolisers may experience life-threatening opioid toxicity. In South Africa, SAHPRA’s scheduling restrictions on codeine-containing products reflect awareness of this variability.

Prontosil, the first sulfonamide antibiotic, is a classic historical example of a prodrug. Prontosil itself is pharmacologically inactive but is reduced by bacterial azo reductase (not present in human tissues) to sulfanilamide, the active antibacterial compound. This discovery was instrumental in establishing the concept of metabolic activation and demonstrated that metabolism can be a species-specific phenomenon.

Levodopa is converted to dopamine by aromatic L-amino acid decarboxylase (AADC). Dopamine itself does not cross the blood-brain barrier, but levodopa does. The peripheral conversion of levodopa to dopamine (by peripheral AADC) is responsible for many of levodopa’s side effects; this is why levodopa is almost always administered with a peripheral DOPA decarboxylase inhibitor (benserazide or carbidopa), which prevents peripheral conversion and allows more levodopa to reach the CNS. This combination is a textbook example of rational prodrug/enzyme-inhibitor coadministration.

Cyclophosphamide and ifosfamide are alkylating agent prodrugs used in cancer chemotherapy. They require hepatic CYP-mediated activation (primarily by CYP2B6 and CYP3A4) to produce the active phosphoramide mustard and acrolein metabolites. Acrolein is responsible for the haemorrhagic cystitis associated with cyclophosphamide; this is prevented by coadministration of mesna (2-mercaptoethane sulfonate), which binds and inactivates acrolein in the urine. South African oncologists commonly use mesna prophylaxis in regimens incorporating ifosfamide and high-dose cyclophosphamide.

Tamoxifen is a selective estrogen receptor modulator (SERM) used in breast cancer treatment. It undergoes extensive metabolism by CYP enzymes (CYP2D6, CYP3A4, CYP2C9) to produce active metabolites including 4-hydroxytamoxifen and endoxifen, which are substantially more potent estrogen receptor antagonists than the parent compound. CYP2D6 poor metabolisers produce lower levels of endoxifen and may have reduced tamoxifen efficacy, though this remains an area of active research and clinical debate.

5.2 Rational Design of Prodrugs

The rationale for prodrug design includes several strategies. Absorption enhancement: Drugs that are poorly absorbed from the gastrointestinal tract may be converted to more lipophilic prodrugs that are better absorbed, then activated systemically. Site-specific delivery: Prodrugs may be designed to be activated only by enzymes present in target tissues. Reduced toxicity: By altering the distribution or metabolic pathway of a drug, prodrugs can reduce toxicity to sensitive tissues. Improved stability: Some prodrugs have improved chemical stability, extending shelf life or allowing formulation as oral liquids for drugs that are otherwise unstable in aqueous solution.

---

6. Pharmacogenetics of Drug Metabolism

Pharmacogenetics is the study of the role of genetic variation in determining drug response. Genetic polymorphisms in drug-metabolising enzymes are a major source of interindividual variability in drug efficacy and toxicity. These polymorphisms may result in absent, reduced, or increased enzyme activity, leading to phenotypic classifications of poor, intermediate, extensive, and ultrarapid metabolisers.

6.1 CYP2D6 Polymorphism

CYP2D6 is located on chromosome 22 and exhibits extensive genetic polymorphism with over 100 known variant alleles. Alleles are classified as functional (1 is the wild-type, fully functional allele), reduced function, or non-functional. Common variant alleles include CYP2D61 (wild-type, fully functional), CYP2D62 (reduced function), CYP2D63, *4, *5, and 6 (non-functional), and CYP2D62xN and *41xN (gene duplications/multiplications that result in ultra-rapid metabolism).

Phenotype frequencies in South Africa vary across population groups. Poor metabolisers (homozygous for non-functional alleles, e.g., *4/4) occur in approximately 5–10% of Caucasian populations but may be less common in some African populations, where different CYP2D6 variant alleles predominate. Ultra-rapid metabolisers (carrying gene duplications) are particularly common in some African populations, where allele frequencies of CYP2D62xN can reach 20–30% or higher, compared to 1–5% in European populations.

6.2 TPMT Polymorphism

Thiopurine methyltransferase (TPMT) deficiency is one of the most clinically important pharmacogenetic conditions. TPMT catalyses the S-methylation of 6-mercaptopurine and azathioprine, inactivating these drugs. Individuals with TPMT deficiency (approximately 1 in 300 are poor metabolisers) accumulate high concentrations of cytotoxic thioguanine nucleotides when treated with standard thiopurine doses, causing severe myelosuppression. This is a particular concern in paediatric oncology and in patients with inflammatory bowel disease or autoimmune conditions treated with azathioprine.

In South Africa, TPMT testing is recommended before initiating thiopurine therapy. Where genotyping is not available, starting at reduced doses and monitoring complete blood count (CBC) closely is an alternative approach, though it is less reliable than prospective genotyping.

6.3 CYP2C9 and Warfarin Dosing

CYP2C9 polymorphism is clinically most significant in warfarin dosing. The CYP2C92 and CYP2C93 alleles are associated with reduced enzyme activity and impaired clearance of S-warfarin, leading to higher-than-expected INR values at standard doses and increased risk of bleeding. Pharmacogenetic-based warfarin dosing algorithms incorporate CYP2C9 genotype (along with VKORC1 genotype, age, and body surface area) to predict maintenance dose more accurately. In South Africa, several academic hospitals and private laboratories offer warfarin pharmacogenetic testing, and the South African Hypertension Society guidelines acknowledge the role of genetic testing in difficult-to-manage anticoagulation.

6.4 Clinical Implementation of Pharmacogenetics

The clinical implementation of pharmacogenetics in South Africa faces several challenges, including the cost of genetic testing, limited availability outside major urban centres, and the need for greater pharmacist and prescriber education. However, the South African Pharmacy Council has increasingly incorporated pharmacogenetics into continuing professional development programmes, and several South African universities have introduced pharmacogenetics modules into their pharmacy undergraduate curricula. The SAPC examination may test candidates on their understanding of clinically actionable pharmacogenetic interactions, particularly those involving CYP2D6, CYP2C19, CYP2C9, and TPMT.

---

7. Enzyme Induction and Inhibition

The activity of drug-metabolising enzymes is not static; it is dynamically altered by exposure to certain chemicals, drugs, herbs, and environmental factors. This dynamic regulation is a major source of drug-drug interactions, therapeutic failure, and adverse drug reactions.

7.1 Enzyme Induction

Enzyme induction refers to the increase in the synthesis or decrease in the degradation of a drug-metabolising enzyme, resulting in increased enzyme activity. Induction is typically a transcriptional effect: the inducing agent activates nuclear receptors (such as the constitutive androstane receptor, CAR, and the pregnane X receptor, PXR) that increase the transcription of CYP genes, leading to increased enzyme protein synthesis. Enzyme induction usually takes 1–3 weeks to reach a new steady state, as it depends on the synthesis of new enzyme protein. Similarly, when an inducing agent is discontinued, enzyme activity gradually returns to baseline as the induced enzyme is degraded.

Mechanisms of induction: The constitutive androstane receptor (CAR) and the pregnane X receptor (PXR) are nuclear receptors that sense the presence of foreign chemicals and upregulate the expression of Phase I and Phase II enzymes, as well as drug transporters. Rifampicin is a prototypical PXR agonist and a potent inducer of CYP3A4, CYP2C9, CYP2C19, and several Phase II enzymes. Carbamazepine, phenytoin, and phenobarbital are both CAR and PXR agonists and are among the most clinically important enzyme inducers.

Major enzyme inducers and their affected CYP enzymes:

Rifampicin (the most potent CYP inducer in clinical use):

• Induces: CYP3A4, CYP2C9, CYP2C19, CYP1A2 (modest), P-glycoprotein
• Clinical consequences: Reduced plasma concentrations of oral contraceptives (risk of unintended pregnancy), warfarin (subtherapeutic INR), cyclosporine and tacrolimus (transplant rejection), protease inhibitors and NNRTIs (HIV treatment failure), direct oral anticoagulants (apixaban, rivaroxaban — though edoxaban is less affected), and many other drugs
• South African context: Rifampicin is a cornerstone of first-line tuberculosis treatment in South Africa. Pharmacists dispensing TB medications should specifically counsel patients that rifampicin reduces the efficacy of oral contraceptives and should advise on additional non-hormonal contraceptive methods during TB treatment.

Carbamazepine, phenytoin, and phenobarbital (anticonvulsant inducers):

• Induce: CYP3A4, CYP2C9, CYP2C19, CYP1A2, CYP2B6, UGT enzymes
• Clinical consequences: Reduced efficacy of warfarin, oral contraceptives, many antidepressants and antipsychotics, calcium channel blockers, statins, and glucocorticoids

St. John’s Wort (Hypericum perforatum):

• Induces: CYP3A4, P-glycoprotein (through activation of PXR)
• Clinical consequence: Reduced plasma concentrations of oral contraceptives, warfarin, cyclosporine, protease inhibitors, and other CYP3A4 substrates; therapeutic failure of immunosuppressants leading to transplant rejection

Smoking (cigarette smoke contains polycyclic aromatic hydrocarbons that induce CYP1A2):

• Clinical consequence: Increased clearance of theophylline, clozapine, and olanzapine; dose requirements are higher in smokers

Chronic alcohol use:

• Induces CYP2E1; may increase metabolism of some drugs while decreasing metabolism of others through competitive effects

7.2 Enzyme Inhibition

Enzyme inhibition refers to the decrease in the activity of a drug-metabolising enzyme, which may result from competitive binding at the active site, non-competitive inhibition, or irreversible (mechanism-based) inhibition in which the inhibitor is metabolised to a reactive intermediate that irreversibly inactivates the enzyme. Inhibition usually occurs rapidly (within hours to days) and is often immediately clinically apparent upon initiation of the inhibitory drug.

Mechanism-based (irreversible) inhibition is particularly clinically significant because the effect persists until new enzyme protein is synthesised (which may take several days to weeks). Several macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) are metabolised by CYP3A4 to reactive intermediates that irreversibly bind to and inactivate the enzyme — this is called suicide inhibition. Ketoconazole and itraconazole are also potent mechanism-based inhibitors of CYP3A4.

Major enzyme inhibitors and their affected CYP enzymes:

Ciprofloxacin and fluoroquinolone antibiotics:

• Inhibit: CYP1A2 (clinically significant)
• Clinical consequence: Increased theophylline concentrations; risk of theophylline toxicity

Fluvoxamine:

• Inhibits: CYP1A2 (very potent), CYP2C19, CYP2C9
• Clinical consequence: Significantly increased theophylline concentrations; increased plasma concentrations of clozapine, olanzapine, and tricyclic antidepressants

Fluoxetine and paroxetine:

• Inhibit: CYP2D6 (potent); fluoxetine also inhibits CYP2C19
• Clinical consequence: Increased plasma concentrations of CYP2D6 substrates (tramadol, codeine, metoprolol, haloperidol, risperidone); paroxetine is one of the most potent CYP2D6 inhibitors among antidepressants

Ketoconazole and itraconazole:

• Inhibit: CYP3A4 (potent); also inhibit some other CYP enzymes
• Clinical consequence: Markedly increased plasma concentrations of CYP3A4 substrates including statins (risk of rhabdomyolysis with simvastatin), cyclosporine and tacrolimus (nephrotoxicity), benzodiazepines (excessive sedation), and many others

Erythromycin and clarithromycin:

• Inhibit: CYP3A4 (potent mechanism-based inhibition by erythromycin; clarithromycin is also a potent inhibitor)
• Clinical consequence: Increased plasma concentrations of CYP3A4 substrates; interaction with carbamazepine (increased carbamazepine levels and neurotoxicity), statins (simvastatin and lovastatin are contraindicated with clarithromycin)

Ritonavir and cobicistat:

• Inhibit: Multiple CYP enzymes (ritonavir is one of the most potent CYP3A4 inhibitors available; cobicistat is a CYP3A4 inhibitor specifically designed for this purpose in HIV treatment)
• Clinical consequence: Ritonavir is used therapeutically as a CYP3A4 “booster” to increase plasma concentrations of other protease inhibitors; however, it also dramatically increases concentrations of many unrelated drugs (carbamazepine, certain benzodiazepines, statins), leading to potentially life-threatening interactions

Grapefruit juice (furanocoumarins):

• Inhibits: Intestinal CYP3A4 (not hepatic CYP3A4)
• Clinical consequence: Increased oral bioavailability of CYP3A4 substrates; most clinically significant with simvastatin and lovastatin (increased risk of myopathy/rhabdomyolysis); patients should avoid grapefruit juice or switch to a non-CYP3A4-dependent statin

7.3 Combined Induction and Inhibition

Some drugs and herbs can both induce and inhibit different metabolic pathways. For example, carbamazepine is primarily an inducer of many CYP enzymes, but it also inhibits CYP2C9, creating a complex net effect on drugs metabolised by both pathways. The net clinical effect may be unpredictable, and therapeutic drug monitoring is often warranted when such drugs are coadministered.

Table 3: Common Drug-Drug Interactions via Enzyme Induction and Inhibition

Victim Drug	Metabolic Pathway	Perpetrator	Mechanism	Clinical Consequence
Warfarin	CYP2C9 (S-warfarin)	Fluconazole, amiodarone, metronidazole	Inhibition	Bleeding risk; increased INR
Warfarin	CYP2C9 (S-warfarin)	Rifampicin, carbamazepine	Induction	Subtherapeutic INR; thrombosis risk
Theophylline	CYP1A2	Ciprofloxacin, fluvoxamine	Inhibition	Theophylline toxicity (nausea, seizures)
Theophylline	CYP1A2	Cigarette smoke	Induction	Subtherapeutic levels in smokers
Clopidogrel	CYP2C19 activation	Omeprazole, esomeprazole	Inhibition	Reduced antiplatelet effect; CV events
Simvastatin	CYP3A4	Clarithromycin, ketoconazole	Inhibition	Rhabdomyolysis risk
Simvastatin	CYP3A4	Rifampicin	Induction	Reduced efficacy; increased dose may be needed
Cyclosporine	CYP3A4	St. John’s Wort	Induction	Transplant rejection
Oral contraceptives	CYP3A4	Rifampicin, carbamazepine	Induction	Contraceptive failure; breakthrough bleeding
Methadone	CYP3A4	Fluconazole	Inhibition	QT prolongation; respiratory depression

---

8. Hepatic Clearance and Its Determinants

Hepatic clearance (CLH) of a drug is determined by two factors: the intrinsic clearance (CLint) of the liver to metabolise the drug in the absence of blood flow limitations, and hepatic blood flow (QH). The relationship between these factors is described by the well-stirred model of hepatic clearance:

CLH = QH × (CLint / (QH + CLint))

From this equation, it follows that for high-extraction drugs (high CLint relative to QH), clearance is flow-limited — it depends primarily on hepatic blood flow. For low-extraction drugs (low CLint relative to QH), clearance is capacity-limited — it depends primarily on the intrinsic metabolic capacity of the liver (i.e., enzyme activity).

This distinction has critical implications for drug interactions and disease states. In liver cirrhosis, both hepatic blood flow and intrinsic metabolic capacity are reduced. For flow-limited drugs, the reduction in hepatic blood flow leads to substantially reduced clearance. For capacity-limited drugs, the reduction in enzyme activity leads to reduced clearance. The net effect is that cirrhosis disproportionately affects the clearance of high-extraction drugs such as propranolol, verapamil, and lidocaine.

In heart failure, hepatic blood flow is reduced owing to reduced cardiac output, leading to reduced clearance of flow-limited drugs. This is one reason why dose reduction is required for drugs such as morphine and midazolam in patients with heart failure.

---

9. Enterohepatic Recirculation

Enterohepatic recirculation (also called enterohepatic cycling) refers to the process by which a drug or metabolite is excreted in bile, delivered to the intestinal lumen, reabsorbed from the intestine, and returned to the liver via the portal circulation. This process can substantially extend the elimination half-life of a drug, as each cycle of biliary excretion and reabsorption effectively recycles the drug and delays its eventual elimination.

The process involves several steps: hepatic metabolism and conjugation (usually glucuronidation), biliary excretion of the conjugate, hydrolysis of the conjugate by bacterial beta-glucuronidase in the intestine (liberating the parent drug or Phase I metabolite), reabsorption of the liberated compound, and portal return to the liver where the cycle may repeat. Enterohepatic recirculation is particularly important for drugs that form glucuronide conjugates that are substrates for bacterial beta-glucuronidase — examples include estradiol, paracetamol (minor pathway), and certain NSAIDs.

From a clinical perspective, interruption of enterohepatic recirculation can significantly alter drug exposure. Antibiotics that disrupt the gut flora can reduce bacterial beta-glucuronidase activity, thereby reducing the reabsorption of drugs that depend on this pathway and potentially reducing their duration of action. Conversely, when an antibiotic that causes such disruption is discontinued, the recovery of gut flora and beta-glucuronidase activity may lead to a sudden increase in reabsorption and a rebound increase in drug concentrations.

---

10. Special Populations

10.1 Hepatic Impairment

In patients with liver disease (cirrhosis, hepatitis, hepatocellular carcinoma), the metabolic capacity of the liver is compromised. The Child-Pugh classification and the Model for End-Stage Liver Disease (MELD) score are used to stratify the severity of hepatic impairment and guide drug dosing. In general, drugs with narrow therapeutic indices that are primarily metabolised by the liver require dose reduction in hepatic impairment. Examples include warfarin, phenytoin, morphine, midazolam, and many others. The SAPC examination frequently tests candidates on dose adjustment in liver disease, and candidates should be familiar with the general principle that drugs metabolised by Phase I oxidation (CYP-dependent pathways) are more affected in liver disease than drugs metabolised by Phase II glucuronidation alone.

South Africa has a high burden of liver disease, driven largely by chronic hepatitis B and C infections, alcohol-related liver disease, and (increasingly) non-alcoholic fatty liver disease (NAFLD). Pharmacists in South African healthcare settings frequently encounter patients with hepatic impairment and must be competent in dose-adjustment decisions.

10.2 Renal Impairment

While the kidneys are primarily an excretory organ, renal impairment can significantly affect drug metabolism. Reduced renal function can lead to the accumulation of both parent drugs and metabolites, some of which may be pharmacologically active or toxic. For example, the active metabolite of morphine, morphine-6-glucuronide, accumulates in renal failure and contributes to enhanced opioid effect and toxicity. Similarly, the active metabolites of primidone, the Phase I metabolite of procainamide (N-acetylprocainamide, NAPA), and the inactive but potentially toxic metabolites of certain drugs accumulate in renal impairment.

Pharmacists should be familiar with the use of glomerular filtration rate (GFR) estimation — using creatinine clearance calculated from serum creatinine, age, weight, and sex — to guide dose adjustments in renal impairment. The South African Medicines Formulary (SAMF) provides guidance on dose adjustment in renal impairment for many drugs, and pharmacists should consult this resource when dispensing for patients with chronic kidney disease.

10.3 Elderly

The elderly represent a population with altered drug metabolism due to the physiological changes of aging, including reduced hepatic mass and blood flow, reduced renal function, changes in body composition (increased fat mass, decreased lean body mass), and polypharmacy. The reduction in hepatic blood flow (which can decline by 30–40% between the ages of 25 and 65) particularly affects the clearance of flow-limited drugs. Phase I oxidative metabolism is generally more affected by aging than Phase II conjugation reactions, making glucuronidated drugs (such as lorazepam and oxazepam) relatively preferable for use in the elderly compared to drugs that undergo extensive CYP oxidation.

South Africa’s elderly population is growing, and the management of polypharmacy in older patients is an increasingly important challenge in both primary healthcare and specialist settings. The SAPC examination may test candidates on their understanding of the pharmacological principles underlying altered drug response in the elderly.

10.4 Neonates and Paediatrics

Drug metabolism in neonates and young children differs substantially from adults. Neonates have immature hepatic enzyme systems — particularly the CYP enzymes — and reduced glucuronidation capacity. This leads to prolonged elimination half-lives of drugs such as chloramphenicol (causing the grey baby syndrome), caffeine, and phenytoin in neonates. Sulfation remains a relatively functional pathway in neonates and may compensate to some extent for immature glucuronidation. CYP3A7 is the predominant CYP enzyme in the fetal liver and gradually transitions to the adult pattern of CYP3A4 predominance over the first few months of life.

In South Africa, neonatal jaundice is a common condition, and the use of drugs that can displace bilirubin from albumin (such as sulfonamides and ceftriaxone) or impair bilirubin conjugation in neonates is particularly important. The South African Standard Treatment Guidelines incorporate specific warnings about drug use in neonates, and pharmacists dispensing medications for neonates should be particularly vigilant.

---

11. Therapeutic Drug Monitoring in Metabolism

Therapeutic drug monitoring (TDM) is the clinical practice of measuring drug plasma concentrations to guide individualised dosing. While TDM is useful for many drugs, it is most valuable for drugs with a narrow therapeutic index, high interindividual variability in pharmacokinetics (often due to metabolic differences), and a clear relationship between plasma concentration and therapeutic or toxic effect.

Drugs where metabolic pathways are routinely monitored through TDM:

• Phenytoin: Metabolised by CYP2C9 and CYP2C19; dose is titrated to achieve a therapeutic range of 10–20 mg/L; genetic polymorphisms in CYP2C9 contribute to interindividual variability
• Carbamazepine: Auto-induced metabolism by CYP3A4; therapeutic range 4–12 mg/L; enzyme induction complicates dosing
• Theophylline: Narrow therapeutic index (10–20 mg/L); metabolic clearance is influenced by CYP1A2 induction/inhibition and smoking status
• Cyclosporine and tacrolimus: Metabolised by CYP3A4; narrow therapeutic index; guided by TDM to prevent graft rejection and nephrotoxicity
• Lamotrigine: Metabolised by glucuronidation; wide therapeutic range but interindividual variability is high; TDM used in some settings

---

12. South African Regulatory and Clinical Context

12.1 SAHPRA and Drug Metabolism Considerations

The South African Health Products Regulatory Authority (SAHPRA) is responsible for the regulation of medicines in South Africa. SAHPRA’s scheduling decisions and product labelling requirements increasingly incorporate metabolic considerations. For example, the restriction of codeine-containing products to prescription-only status was driven by concerns about CYP2D6 polymorphism and the risk of opioid toxicity. SAHPRA also mandates specific labelling for drugs with known metabolic interaction risks, and pharmacists dispensing these medications are expected to provide appropriate counselling.

12.2 Traditional Medicine and Drug Metabolism

Traditional medicine use is prevalent in South Africa, with many patients using herbal remedies concurrently with conventional medicines. Several traditional herbs are potent enzyme inducers or inhibitors with clinically significant interactions. St. John’s Wort, discussed above as a potent CYP3A4 inducer, is used by some patients for mild to moderate depression and can cause therapeutic failure of prescribed antidepressants, oral contraceptives, warfarin, and antiretrovirals. Garlic supplements (Allium sativum) may inhibit CYP2E1 and interact with warfarin. Echinacea may inhibit or induce CYP enzymes in a time-dependent manner. Devils Claw (Harpagophytum) and other traditional remedies used in South Africa for pain and inflammation may interact with CYP enzymes, though the evidence base is less robust.

Pharmacists should routinely enquire about traditional and complementary medicine use when taking medication histories, and should counsel patients about the potential for interactions between traditional medicines and prescribed drugs. This is particularly important for patients on warfarin, antiretrovirals, immunosuppressants, and other drugs with narrow therapeutic indices.

12.3 TB-HIV Integration and Metabolic Drug Interactions

South Africa’s twin epidemics of tuberculosis and HIV create a particularly complex metabolic drug interaction landscape. Rifampicin, a cornerstone of TB treatment, is one of the most potent enzyme inducers in clinical medicine. Many antiretroviral drugs are substrates of CYP enzymes that are induced by rifampicin, leading to substantially reduced plasma concentrations and risk of therapeutic failure. The South African HIV treatment guidelines (aligned with WHO recommendations) address these interactions in detail, and pharmacists managing both TB and HIV medications must carefully navigate the interaction profiles. For example, the interaction between rifampicin and efavirenz requires dose adjustment of efavirenz (the standard dose of 600 mg daily is generally maintained, though higher doses may be considered in patients weighing >60 kg).

12.4 The South African Medicines Formulary and Metabolic Guidance

The South African Medicines Formulary (SAMF) provides comprehensive guidance on drug dosing, including adjustments for hepatic and renal impairment, and highlights clinically important metabolic drug interactions. The SAPC examination expects candidates to be familiar with SAMF guidance and to be able to apply pharmacokinetic principles to individualise drug therapy in complex patients. Candidates should note that the SAMF is updated regularly and should use the most current edition when preparing for the examination.

---

13. Drug Interactions Involving Transporters

While this chapter focuses on metabolic drug-drug interactions, it is important to recognise that drug transporters — particularly P-glycoprotein (P-gp, encoded by the ABCB1 gene) and organic anion transporting polypeptides (OATPs) — are intimately involved in drug absorption, distribution, and elimination, and their interplay with metabolising enzymes determines overall drug exposure. P-glycoprotein is an ATP-dependent efflux transporter that pumps drugs out of enterocytes (limiting absorption), out of hepatocytes and renal tubular cells (promoting biliary and renal excretion), and out of the brain (contributing to the blood-brain barrier). Many CYP3A4 substrates are also P-gp substrates, and the coordinated induction of both CYP3A4 and P-gp by rifampicin and St. John’s Wort is an important mechanism of drug interactions.

The interplay between CYP3A4 and P-gp in the gut wall is particularly significant: CYP3A4 metabolises drugs within enterocytes while P-gp actively pumps drugs back into the intestinal lumen, where they can be reabsorbed. This combined action effectively limits the oral bioavailability of drugs such as cyclosporine, tacrolimus, and many calcium channel blockers. Inhibitors of either pathway can significantly alter this delicate balance.

---

14. Examination Focus Areas and SAPC-Specific Guidance

The SAPC examination frequently tests the following areas related to drug metabolism, based on analysis of past papers and the SAPC competency framework:

High-yield topics for the SAPC examination:

1. CYP enzyme polymorphisms: Candidates should be able to identify the major polymorphic CYP enzymes (CYP2D6, CYP2C9, CYP2C19), explain the phenotypic consequences (poor, intermediate, extensive, ultra-rapid metabolisers), and describe at least two clinical scenarios where this polymorphism has therapeutic implications. The clopidogrel-CYP2C19 and codeine-CYP2D6 interactions are the most frequently examined.

2. Phase I vs Phase II reactions: Candidates should be able to distinguish between Phase I (oxidation, reduction, hydrolysis — primarily CYP-mediated) and Phase II (conjugation with glucuronic acid, sulfate, acetyl, methyl, glutathione groups) reactions, give examples of drugs metabolised by each pathway, and explain why Phase II metabolites are generally more water-soluble.

3. Enzyme induction and inhibition: Candidates should be able to identify the major inducers and inhibitors of CYP3A4, CYP2C9, CYP1A2, and CYP2D6, predict the clinical consequences of adding or withdrawing an inducing or inhibiting drug, and advise on appropriate monitoring strategies.

4. First-pass metabolism: Candidates should explain the anatomical basis of first-pass metabolism, identify at least three drugs with significant first-pass metabolism, and explain why the oral dose of these drugs is higher than the IV dose.

5. Prodrug activation: Candidates should be able to identify at least three prodrugs and their activating enzymes, explain the clinical significance of impaired prodrug activation (clopidogrel and CYP2C19 is the most important), and describe how prodrug design can be used to improve therapy.

6. Paracetamol toxicity: Candidates must have a thorough understanding of the metabolic basis of paracetamol hepatotoxicity — the saturation of sulfate conjugation at toxic doses, the CYP2E1-mediated formation of NAPQI, the protective role of glutathione, and the mechanism and timing of N-acetylcysteine therapy.

7. Therapeutic drug monitoring: Candidates should be able to identify drugs where TDM is indicated, explain the relationship between plasma concentration and effect, and suggest appropriate dose adjustments based on drug levels and clinical factors.

8. Special populations: Candidates should understand how hepatic impairment, renal impairment, elderly patients, and neonates alter drug metabolism and explain how dosing should be adjusted in each population.

---

Definitions of Key Terms

Bioavailability (F): The fraction of an administered dose that reaches the systemic circulation unchanged, expressed as a fraction (0–1) or percentage (0–100%). Oral bioavailability is affected by absorption, first-pass metabolism, and efflux transporters.

Cytochrome P450 (CYP): A superfamily of haem-containing enzymes (monooxygenases) located in the smooth endoplasmic reticulum that catalyse the oxidation of drugs and endogenous compounds.

Enzyme induction: An increase in the synthesis or activity of a drug-metabolising enzyme, leading to increased drug clearance and reduced plasma concentrations.

Enzyme inhibition: A decrease in the activity of a drug-metabolising enzyme, leading to decreased drug clearance and increased plasma concentrations. May be competitive, non-competitive, or mechanism-based (irreversible).

First-pass metabolism: The metabolism of a drug during its initial passage through the gastrointestinal tract, portal circulation, and liver before reaching the systemic circulation. Responsible for the low oral bioavailability of many drugs.

Glucuronidation: A Phase II conjugation reaction in which glucuronic acid is transferred from UDPGA to a drug or metabolite, producing a highly water-soluble glucuronide.

Hepatic clearance: The volume of plasma cleared of drug per unit time by the liver. Determined by hepatic blood flow and the intrinsic metabolic capacity of hepatic enzymes.

Metabolic activation: The conversion of an inactive prodrug to its pharmacologically active form by metabolic processes, typically catalysed by CYP or other Phase I enzymes.

Phase I reactions: Functionalisation reactions — primarily oxidation, reduction, and hydrolysis — that introduce or expose a functional group on a drug molecule. Primarily mediated by CYP enzymes.

Phase II reactions: Conjugation reactions in which an endogenous molecule (glucuronic acid, sulfate, acetyl group, methyl group, glutathione, amino acid) is attached to the drug or its Phase I metabolite to increase water solubility and facilitate excretion.

Pharmacogenetics: The study of how genetic variation in drug-metabolising enzymes, drug targets, and transporters affects individual drug response.

Poor metaboliser (PM): An individual with two non-functional alleles of a drug-metabolising enzyme, resulting in markedly reduced or absent enzyme activity.

Prodrug: An inactive or weakly active drug that requires metabolic activation to exert its pharmacological effect.

Therapeutic drug monitoring (TDM): The measurement of drug plasma concentrations to optimise dosing and minimise toxicity, particularly for drugs with narrow therapeutic indices.

Ultra-rapid metaboliser (UM): An individual with gene duplications or multiplications of a functional drug-metabolising enzyme allele, resulting in markedly increased enzyme activity.

---

Clinical Pearls for Practice

Pearl 1 — Theophylline in smokers: A patient with asthma who is a heavy smoker may require up to 50–100% higher theophylline doses than a non-smoker to achieve therapeutic concentrations because of CYP1A2 induction by polycyclic aromatic hydrocarbons in cigarette smoke. When the patient stops smoking, the enzyme induction dissipates and theophylline levels can rise into the toxic range within days to weeks. Always reassess theophylline dosing when a patient’s smoking status changes.

Pearl 2 — Clopidogrel and PPIs: The interaction between omeprazole and clopidogrel is frequently misunderstood. While the CYP2C19 inhibition by omeprazole is real, the clinical magnitude of this interaction and its impact on cardiovascular outcomes remains debated. From an examination perspective, the principle is clear: avoid potent CYP2C19 inhibitors (omeprazole, esomeprazole) with clopidogrel, or use an alternative PPI such as pantoprazole (which has minimal CYP2C19 inhibitory activity). However, the most important principle is that clopidogrel should be dosed as directed regardless, and patients should not stop their antiplatelet therapy without consulting their cardiologist.

Pearl 3 — Warfarin and antibiotics: The interaction between warfarin and antibiotics is one of the most common and dangerous metabolic interactions in clinical practice. Antibiotics can increase INR by inhibiting the production of vitamin K by gut bacteria (reducing vitamin K availability) and/or by inhibiting CYP2C9-mediated warfarin metabolism. When dispensing antibiotics to a patient on warfarin, always check the INR within 3–5 days of starting the antibiotic and counsel the patient about signs of bleeding or clotting.

Pearl 4 — Codeine in breastfeeding: Codeine is contraindicated in breastfeeding mothers in many guidelines because of the risk of morphine accumulation in breastfed infants, particularly if the mother is a CYP2D6 ultra-rapid metaboliser. Neonates are particularly susceptible to opioid toxicity because of their immature metabolic capacity. South African prescribing guidelines similarly caution against codeine use in breastfeeding.

Pearl 5 — Paracetamol overdose timing: In paracetamol overdose, N-acetylcysteine (NAC) is most effective when administered within 8 hours of ingestion. After 8 hours, the risk of hepatotoxicity increases substantially, and the benefit of NAC diminishes. At 24 hours or more, NAC may still be life-saving but the risk of liver failure is high. The Rumack-Matthew nomogram is used to determine the need for NAC based on the serum paracetamol concentration plotted against time since ingestion. Never delay NAC treatment pending confirmatory blood tests if the history strongly suggests significant overdose.

---

Summary

Drug metabolism is a fundamental pillar of clinical pharmacology and an indispensable topic for the SAPC examination. The liver’s cytochrome P450 enzyme system, with its major isoforms CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, is responsible for the biotransformation of the vast majority of clinically used drugs. Phase I oxidative reactions are complemented and followed by Phase II conjugation reactions that produce highly water-soluble metabolites for renal or biliary excretion. Genetic polymorphisms in metabolic enzymes produce clinically important phenotypes of poor, intermediate, extensive, and ultra-rapid metabolisers, which explain much of the interindividual variability in drug response.

Enzyme induction and inhibition represent the most clinically significant drug-drug interactions in medicine. Rifampicin, anticonvulsants, and St. John’s Wort are potent enzyme inducers capable of causing therapeutic failure of many coadministered drugs, while macrolides, azole antifungals, and grapefruit juice are potent inhibitors capable of causing drug toxicity. First-pass metabolism determines oral bioavailability and is the basis for route-of-administration decisions. Prodrug design exploits metabolic pathways to improve drug therapy, but polymorphisms in the activating enzymes can paradoxically render prodrugs ineffective or toxic in certain individuals.

The South African clinical context — including the high burden of tuberculosis and HIV, the prevalent use of traditional medicines, the regulatory framework established by SAHPRA, and the availability of guidance in the SAMF — frames these principles in a locally relevant context that the SAPC examination expects candidates to understand and apply. Competent pharmacists must be able to identify metabolic drug interactions, advise on dose adjustments, monitor for therapeutic efficacy and toxicity, and counsel patients on the safe and effective use of medicines in the context of their individual metabolic profile.